⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ONCY News
Oncolytics Biotech, Inc. Common Shares
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
globenewswire.com
NTHI
BCTX
ONCY
Form 8-K
sec.gov
ONCY
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
globenewswire.com
ONCY
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
prnewswire.com
AMGN
CGON
CLNN
RPRX
BTAI
ONCY
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN
Form 8-K
sec.gov
ONCY
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
globenewswire.com
ONCY
Form 8-K
sec.gov
ONCY
Form 8-K
sec.gov
ONCY
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
globenewswire.com
ONCY